Lyrfigtu (lirafugratinib)
Elevar Therapeutics
ApprovedSep 23, 2026
Marketer take
Limited to previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma, so molecular testing rates and reach into GI oncology centers define the market, and existing FGFR inhibitor brands face a direct rival.
- Sponsor company
- Elevar Therapeutics
- Indication
- To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Sep 23, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?